BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38688591)

  • 1. HECTD2/TNFAIP1 Axis Regulating the p38/JNK Pathway to Promote an Inflammatory Response in Renal Cell Carcinoma Cells.
    Lv D; Chen Y; Tang L; Tian Y; Ren D; Jian N; Shen T
    In Vivo; 2024; 38(3):1094-1103. PubMed ID: 38688591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human gut-microbiome-derived propionate coordinates proteasomal degradation via HECTD2 upregulation to target EHMT2 in colorectal cancer.
    Ryu TY; Kim K; Han TS; Lee MO; Lee J; Choi J; Jung KB; Jeong EJ; An DM; Jung CR; Lim JH; Jung J; Park K; Lee MS; Kim MY; Oh SJ; Hur K; Hamamoto R; Park DS; Kim DS; Son MY; Cho HS
    ISME J; 2022 May; 16(5):1205-1221. PubMed ID: 34972816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIF-1α Induces HECTD2 Up-Regulation and Aggravates the Malignant Progression of Renal Cell Cancer
    Lv D; Shen T; Yao J; Yang Q; Xiang Y; Ma Z
    Front Cell Dev Biol; 2021; 9():775642. PubMed ID: 35004677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
    Shang D; Han T; Xu X; Liu Y
    Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
    Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
    Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-33 Predicts Poor Prognosis and Promotes Renal Cell Carcinoma Cell Growth Through its Receptor ST2 and the JNK Signaling Pathway.
    Wu CW; Wu YG; Cheng C; Hong ZD; Shi ZM; Lin SQ; Li J; He XY; Zhu AY
    Cell Physiol Biochem; 2018; 47(1):191-200. PubMed ID: 29763892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cullin3-TNFAIP1 E3 Ligase Controls Inflammatory Response in Hepatocellular Carcinoma Cells via Ubiquitination of RhoB.
    Liu Y; Zhang W; Wang S; Cai L; Jiang Y; Pan Y; Liang Y; Xian J; Jia L; Li L; Zhao H; Zhang Y
    Front Cell Dev Biol; 2021; 9():617134. PubMed ID: 33553178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
    Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
    EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of transforming growth factor-beta type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma.
    Fukasawa H; Yamamoto T; Fujigaki Y; Misaki T; Ohashi N; Takayama T; Suzuki S; Mugiya S; Oda T; Uchida C; Kitagawa K; Hattori T; Hayashi H; Ozono S; Kitagawa M; Hishida A
    Int J Cancer; 2010 Oct; 127(7):1517-25. PubMed ID: 20073064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways.
    Mo C; Dai Y; Kang N; Cui L; He W
    J Biol Chem; 2012 Jun; 287(23):19242-54. PubMed ID: 22493490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.
    Zhang G; Yu Z; Fu S; Lv C; Dong Q; Fu C; Kong C; Zeng Y
    Cancer Gene Ther; 2019 Sep; 26(9-10):323-333. PubMed ID: 30459398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CRL3
    Li L; Zhang W; Liu Y; Liu X; Cai L; Kang J; Zhang Y; Chen W; Dong C; Zhang Y; Wang M; Wei W; Jia L
    Signal Transduct Target Ther; 2020 Apr; 5(1):42. PubMed ID: 32327643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA HOTTIP affects renal cell carcinoma progression by regulating autophagy via the PI3K/Akt/Atg13 signaling pathway.
    Su Y; Lu J; Chen X; Liang C; Luo P; Qin C; Zhang J
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):573-588. PubMed ID: 30511250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuftelin 1 (TUFT1) Promotes the Proliferation and Migration of Renal Cell Carcinoma
    Lin H; Zeng W; Lei Y; Chen D; Nie Z
    Pathol Oncol Res; 2021; 27():640936. PubMed ID: 34257606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.
    Taniguchi H; Ito S; Ueda T; Morioka Y; Kayukawa N; Ueno A; Nakagawa H; Fujihara A; Ushijima S; Kanazawa M; Hongo F; Ukimura O
    Biochem Biophys Res Commun; 2017 Apr; 485(2):267-271. PubMed ID: 28235487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma.
    An J; Liu H; Magyar CE; Guo Y; Veena MS; Srivatsan ES; Huang J; Rettig MB
    Cancer Res; 2013 Feb; 73(4):1374-85. PubMed ID: 23393199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-497 suppresses renal cell carcinoma by targeting VEGFR-2 in ACHN cells.
    Pengcheng S; Ziqi W; Luyao Y; Xiangwei Z; Liang L; Yuwei L; Lechen L; Wanhai X
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28465356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.
    Li Y; Guan B; Liu J; Zhang Z; He S; Zhan Y; Su B; Han H; Zhang X; Wang B; Li X; Zhou L; Zhao W
    EBioMedicine; 2019 Jun; 44():439-451. PubMed ID: 31130475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.
    Wan P; Chen Z; Zhong W; Jiang H; Huang Z; Peng D; He Q; Chen N
    Oncol Rep; 2020 Dec; 44(6):2475-2486. PubMed ID: 33125143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.